KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Notes Payables: 2016-2023

Historic Notes Payables for Emergent BioSolutions (EBS) over the last 7 years, with Dec 2023 value amounting to $413.7 million.

  • Emergent BioSolutions' Notes Payables fell 99.81% to $800,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $800,000, marking a year-over-year decrease of 99.81%. This contributed to the annual value of $413.7 million for FY2023, which is 56.78% down from last year.
  • Emergent BioSolutions' Notes Payables amounted to $413.7 million in FY2023, which was down 56.78% from $957.3 million recorded in FY2022.
  • In the past 5 years, Emergent BioSolutions' Notes Payables ranged from a high of $957.3 million in FY2022 and a low of $12.9 million during FY2019.
  • In the last 3 years, Emergent BioSolutions' Notes Payables had a median value of $413.7 million in 2023 and averaged $467.5 million.
  • In the last 5 years, Emergent BioSolutions' Notes Payables spiked by 2,929.43% in 2022 and then crashed by 56.78% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Notes Payables stood at $12.9 million in 2019, then skyrocketed by 162.02% to $33.8 million in 2020, then fell by 6.51% to $31.6 million in 2021, then soared by 2,929.43% to $957.3 million in 2022, then crashed by 56.78% to $413.7 million in 2023.